These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 9304508)
1. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. Chou YY; Cheng AL; Hsu HC J Gastroenterol Hepatol; 1997 Aug; 12(8):569-75. PubMed ID: 9304508 [TBL] [Abstract][Full Text] [Related]
2. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Linn SC; Honkoop AH; Hoekman K; van der Valk P; Pinedo HM; Giaccone G Br J Cancer; 1996 Jul; 74(1):63-8. PubMed ID: 8679460 [TBL] [Abstract][Full Text] [Related]
3. Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma. Akimoto M; Yoshikawa M; Ebara M; Sato T; Fukuda H; Kondo F; Saisho H World J Gastroenterol; 2006 Feb; 12(6):868-73. PubMed ID: 16521213 [TBL] [Abstract][Full Text] [Related]
4. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Ng IO; Liu CL; Fan ST; Ng M Am J Clin Pathol; 2000 Mar; 113(3):355-63. PubMed ID: 10705815 [TBL] [Abstract][Full Text] [Related]
5. p53 and P-glycoprotein influence chemoresistance in hepatocellular carcinoma. Li S; Gao M; Li Z; Song L; Gao X; Han J; Wang F; Chen Y; Li W; Yang J Front Biosci (Elite Ed); 2018 Jun; 10(3):461-468. PubMed ID: 29772519 [TBL] [Abstract][Full Text] [Related]
6. Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Takeba Y; Sekine S; Kumai T; Matsumoto N; Nakaya S; Tsuzuki Y; Yanagida Y; Nakano H; Asakura T; Ohtsubo T; Kobayashi S Biol Pharm Bull; 2007 Aug; 30(8):1400-6. PubMed ID: 17666793 [TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin Sensitizes Mutant p53 (R248Q)-Expressing Hepatocellular Carcinoma Cells to Doxorubicin by Inhibiting P-gp Expression. Yang Y; He J; Chen J; Lin L; Liu Y; Zhou C; Su Y; Wei H Biomed Res Int; 2019; 2019():8207056. PubMed ID: 31976328 [TBL] [Abstract][Full Text] [Related]
8. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Huang M; Liu G Cancer Lett; 1999 Jan; 135(1):97-105. PubMed ID: 10077227 [TBL] [Abstract][Full Text] [Related]
10. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. Park JG; Lee SK; Hong IG; Kim HS; Lim KH; Choe KJ; Kim WH; Kim YI; Tsuruo T; Gottesman MM J Natl Cancer Inst; 1994 May; 86(9):700-5. PubMed ID: 7908989 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of technetium-99m tetrofosmin liver imaging to detect hepatocellular carcinoma and related to expression of P-glycoprotein or multidrug resistance associated protein-a preliminary report. Ding HJ; Huang WT; Tsai CS; Chang CS; Kao A Nucl Med Biol; 2003 Jul; 30(5):471-5. PubMed ID: 12831984 [TBL] [Abstract][Full Text] [Related]
12. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Park YB; Kim HS; Oh JH; Lee SH Int Orthop; 2001; 24(6):307-10. PubMed ID: 11294418 [TBL] [Abstract][Full Text] [Related]
13. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation. Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422 [TBL] [Abstract][Full Text] [Related]
14. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cheng AL; Chen YC; Yeh KH; Chuang SE; Chen BR; Chen DS Cancer; 1996 Mar; 77(5):872-7. PubMed ID: 8608477 [TBL] [Abstract][Full Text] [Related]
15. Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostaining. Richart J; Brunt EM; Di Bisceglie AM Dig Dis Sci; 2002 Nov; 47(11):2454-8. PubMed ID: 12452378 [TBL] [Abstract][Full Text] [Related]
16. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. Giovannini C; Gramantieri L; Chieco P; Minguzzi M; Lago F; Pianetti S; Ramazzotti E; Marcu KB; Bolondi L J Hepatol; 2009 May; 50(5):969-79. PubMed ID: 19304334 [TBL] [Abstract][Full Text] [Related]
17. [Chemosensitivity test on hepatocellular carcinoma (HCC) and drug resistance]. Ishimura H Hokkaido Igaku Zasshi; 1996 Nov; 71(6):689-98. PubMed ID: 8996838 [TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma and chemotherapy: the role of p53. Brito AF; Abrantes AM; Pinto-Costa C; Gomes AR; Mamede AC; Casalta-Lopes J; Gonçalves AC; Sarmento-Ribeiro AB; Tralhão JG; Botelho MF Chemotherapy; 2012; 58(5):381-6. PubMed ID: 23257706 [TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma. Nakajima A; Yamamoto Y; Taura K; Hata K; Fukumoto M; Uchinami H; Yonezawa K; Yamaoka Y Int J Oncol; 2004 Mar; 24(3):635-45. PubMed ID: 14767548 [TBL] [Abstract][Full Text] [Related]
20. A novel interaction of nucleophosmin with BCL2-associated X protein regulating death evasion and drug sensitivity in human hepatoma cells. Lo SJ; Fan LC; Tsai YF; Lin KY; Huang HL; Wang TH; Liu H; Chen TC; Huang SF; Chang CJ; Lin YJ; Yung BY; Hsieh SY Hepatology; 2013 May; 57(5):1893-905. PubMed ID: 23258611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]